drugset / Trial / NCT02145403
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The investigators hypothesize that adding carfilzomib to standard conditioning regimen for allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant relapse and treatment-related mortality by decreasing severe GVHD, leading to overall improvement in transplant outcomes.
Timeline
- Start
- 2014-10
- Primary completion
- 2018-11-26
- Completion
- 2020-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 20 mg/m2 | Intravenous |
| Background | Tacrolimus | Small molecule | 0.03 mg/kg | — |